ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
-1.03%
Bitcoin
62,948.12
6.47%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. USOTC
  6. Arch Therapeutics Inc (QB) (ARTH)

  7. Arch Therapeutics Inc (QB) (ARTH) Noticias

ARTH

Arch Therapeutics (QB) (ARTH)

Arch Therapeutics Inc (QB)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:USOTC:ARTH
FechaHoraFuenteTítuloSímboloCompañía
22/06/202315:31Edgar (US Regulatory)Current Report Filing (8-k)USOTC:ARTHArch Therapeutics Inc (QB)
23/05/202305:02Edgar (US Regulatory)Quarterly Report (10-q)USOTC:ARTHArch Therapeutics Inc (QB)
16/05/202305:01Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)USOTC:ARTHArch Therapeutics Inc (QB)
25/01/202314:19Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:ARTHArch Therapeutics Inc (QB)
23/01/202316:18Edgar (US Regulatory)Securities Registration Statement (s-1/a)USOTC:ARTHArch Therapeutics Inc (QB)
28/12/202215:52Edgar (US Regulatory)Annual Report (10-k)USOTC:ARTHArch Therapeutics Inc (QB)
31/08/202205:05Edgar (US Regulatory)Notice of Effectiveness (effect)USOTC:ARTHArch Therapeutics Inc (QB)
30/08/202216:21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)USOTC:ARTHArch Therapeutics Inc (QB)
30/08/202205:02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)USOTC:ARTHArch Therapeutics Inc (QB)
22/08/202205:04Edgar (US Regulatory)Securities Registration Statement (s-1)USOTC:ARTHArch Therapeutics Inc (QB)
18/08/202205:03Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)USOTC:ARTHArch Therapeutics Inc (QB)
17/08/202215:11Edgar (US Regulatory)Amended Current Report Filing (8-k/a)USOTC:ARTHArch Therapeutics Inc (QB)
15/08/202215:24Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)USOTC:ARTHArch Therapeutics Inc (QB)
08/07/202216:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)USOTC:ARTHArch Therapeutics Inc (QB)
22/03/202204:14TipRanksDawson James Remains a Buy on Arch Therapeutics (ARTH)USOTC:ARTHArch Therapeutics Inc (QB)
04/01/202215:18Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)USOTC:ARTHArch Therapeutics Inc (QB)
28/12/202115:06Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)USOTC:ARTHArch Therapeutics Inc (QB)
22/12/202115:08Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)USOTC:ARTHArch Therapeutics Inc (QB)
25/02/202111:27Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)USOTC:ARTHArch Therapeutics Inc (QB)
17/10/201916:11Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)USOTC:ARTHArch Therapeutics Inc (QB)
20/07/201812:15Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)USOTC:ARTHArch Therapeutics Inc (QB)
17/11/201612:35Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)USOTC:ARTHArch Therapeutics Inc (QB)
31/10/201616:04Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)USOTC:ARTHArch Therapeutics Inc (QB)
16/07/201607:00InvestorsHub NewsWireInsider Financial Publishes New Research On Three Promising BiotechsUSOTC:ARTHArch Therapeutics Inc (QB)
14/07/201607:33InvestorsHub NewsWireOne Step Vending Corp. KOSK – 230% Growth and Over 150,000 Units SuppliedUSOTC:ARTHArch Therapeutics Inc (QB)
14/10/201505:03Edgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:ARTHArch Therapeutics Inc (QB)
16/06/201407:15MarketwiredArch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine & Targeted Medicine ...USOTC:ARTHArch Therapeutics Inc (QB)
28/05/201408:00MarketwiredArch Therapeutics Inc. to Present at the LD MICRO Invitational 2014 on June 4thUSOTC:ARTHArch Therapeutics Inc (QB)
27/05/201408:00MarketwiredArch Therapeutics Inc. to Present at the Third Annual Marcum MicroCap ConferenceUSOTC:ARTHArch Therapeutics Inc (QB)
01/04/201407:00MarketwiredArch Therapeutics Appoints Chirag Shah, PhD as Vice President of R&D Engineering & Quality Systems & Peter LaCrosse as Chief ...USOTC:ARTHArch Therapeutics Inc (QB)
 Showing the most relevant articles for your search:USOTC:ARTH

Su Consulta Reciente

NYSE
AXP
American Express
USOTC
BASFY
BASF (QX)
CCOM
SILVER
SILVER
NASDAQ
MSFT
Microsoft
CCOM
US500
US 500
NYSE
MRK
Merck
NYSE
JPM
JP Morgan Chase
NYSE
MCD
McDonalds
NASDAQ
AAPL
Apple
FX
EURUSD
Euro vs US Dollar
AMEX
XLE
Energy Select Sector SPDR
COIN
SOLUSD
Solana
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
KO
Coca Cola
FX
USDMXN
US Dollar vs MXN
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados